Sell HIMS by May 14, 2026.

Vance Frost | Clinical Ops Analyst | 20 yrs clinical CEO controls \~90% of voting power via super-voting Class V shares. HIMS built a real cash-pay subscription platform. Then it stepped into the one lane where "scale first, compliance later" doesn't fly. Two businesses, one ticker: 1. The boring one that works: hair/ED/derm/mental health subscriptions. 2. The risky one: mass-marketed compounded GLP-1s pushed through a national funnel. Why the GLP-1 lane got ugly: * Feb 21, 2025: FDA said the …